BLDR — Claude Opus 4.8

I'll research BLDR (Builders FirstSource) to build this earnings preview. Let me gather recent filings, transcripts, news, and stock data.Fiscal labeling here is shifted — the most recent report is 2026Q1 (April 30, 2026), and the year-ago comparison for tomorrow's 2026Q2 is the 2025Q2 report. Let me read the latest release and transcript plus the year-ago release.The fiscal labels are just calendar quarters — tomorrow's "2026Q2" is the quarter ended June 30, 2026. I pulled the wrong year of stock data. Let me correct that and gather the Q1 2026 call transcript plus recent news and peer/macro context.Let me pull recent news/estimates and peer read-through to round out the preview.I have what I need. Let me quickly compute the key stock-performance and guidance math to anchor the preview.# Builders FirstSource (BLDR) — Q2 2026 Earnings Preview Reports: Thursday, July 30, 2026 (before market open) · Conference call 8:00 a.m. Central · Quarter ended June 30, 2026

1. The one-line setup

BLDR heads into its Q2 print as a broken momentum stock in a stubbornly weak housing market. The shares are down ~33% YTD in 2026 and roughly 60% below their early-2025 peak, and they've fallen ~23% in the past month alone into the print (close of $69.72 on 7/29). That is dramatic underperformance versus homebuilders — D.R. Horton is roughly flat YTD and Lennar is down ~18% — which tells you the market views BLDR's problem as margin/deleveraging, not just cyclical volume.

The whole quarter comes down to one question: is the second-half margin recovery management promised still on track, or does guidance get cut again?

2. The bar management itself set

On the Q1 call (April 30), CFO Pete Beckmann gave unusually explicit Q2 guardrails. This is your scorecard:

Metric	Q2'26 guidance	Q2'25 actual	Implied Y/Y
Net sales	$3.75B – $4.05B	$4.23B	-11% to -4%
Adj. EBITDA	$300M – $350M	$506M	-41% to -31%
Implied Adj. EBITDA margin	~7.4% – 9.3%	12.0%	-270 to -460 bps

For reference, Q2 is seasonally BLDR's strongest quarter, so this is a low bar by the company's own history. Year-ago Q2 delivered $1.66 GAAP / $2.38 adjusted EPS; expect a steep step-down again this year.

Full-year 2026 guide (already cut once in April): - Net sales $14.6B–$15.6B; gross margin 27.5%–29% - Adj. EBITDA $1.1B–$1.5B (an extremely wide $400M range — a tell that visibility is poor) - Free cash flow ~$400M–$500M - Assumes single-family and multi-family starts down ~2.5%, R&R down 1%, ~$400/mbf lumber

The critical structural assumption: management said the year is back-half weighted, implying ~9.6% EBITDA margin in 2H vs. ~7.6% in 1H. Q2 is the first real test of that ramp. If Q2 lands at/below the low end and the H2 hockey stick doesn't show up, expect the full-year EBITDA range to be trimmed again — and the stock is already positioned for it.

3. Where Q1 left off (the trajectory)

Q1 2026 was ugly and set a cautious tone: - Net sales $3.29B, -10.1% (core organic -8.3%, of which single-family -11.1%; commodity deflation -3.3%; +1.5% M&A) - Gross margin 28.3%, -220 bps - Adj. EBITDA $214M, -42%, margin just 6.5% - GAAP net loss of $(0.43); adjusted EPS $0.27 (vs. $1.51 a year ago)

Importantly, management said Q1 came in at the upper end of its expected range "even as the macro was worse than we expected," and CEO Peter Jackson flagged that the Middle East conflict surprised the spring selling season by pushing interest rates and inflation higher and denting consumer confidence. That macro backdrop is still live — the 7/28–7/29 news flow shows renewed U.S.–Iran escalation and an oil spike — so don't expect a tone shift toward optimism.

4. Key debates & what to listen for

a) Gross margin — the swing factor. The recurring negative surprise has been specialty/"other" products (siding, roofing, gypsum, cement, etc.), where margins tightened faster than expected. Management ranked specialty as the #1 driver of the margin cut. Watch whether specialty stabilizes and whether the "resets" have now worked all the way through the P&L (lumber → value-add → specialty). Also watch mix: BLDR is leaning back into lower-margin lumber via bundling to fill capacity and win strategic share — good for share, a drag on reported margin.

b) Price/cost and inflation. Diesel/fuel and higher input costs are a ~$100M gross headwind for 2026 that management said it does not expect to fully offset. As a distributor, BLDR passes through via surcharges and pricing, but with a lag and with builders resisting increases on affordability grounds. Commodity lumber has been rising since December — normally a modest tailwind, but truss/manufactured pricing lags on a bid-and-quote basis. Net price/cost commentary will move the margin narrative.

c) Volume & the "value-per-start" drag. Even flat-ish starts translate into weaker sales because homes are smaller/simpler — management estimates a comparable start is worth ~10% less than 2019, plus a ~3-month lag from start to first sale. Single-family down double digits in Q1; watch whether the "daily sales building into April/May" seasonal cadence held through June.

d) Multi-family. Management said quoting is active but rate-driven deferrals mean no meaningful multi-family recovery until 2027. Any change here matters for 2027 setup.

e) Cost actions & share gains. BLDR is executing $100M of cost actions ($75M reductions + $25M avoidance) and $50M–$70M of productivity for the year, with 21 facilities consolidated YTD. It claims to be taking share as smaller/private competitors struggle (layoffs, closures, "unable to pay bills"). Quantifying realized cost savings vs. plan is key to the H2 leverage story.

5. Capital allocation & balance sheet (a real point of tension)

BLDR repurchased 3.3M shares at $92.25 (~$303M) in Q1 and the Board authorized a fresh $500M buyback. Since 2021 it has retired ~50% of shares outstanding.
But leverage is now 3.2x net debt/EBITDA — well above the stated 1–2x comfort zone — on $4.6B net debt and falling EBITDA. Management insists the balance sheet is "bulletproof" and net debt levels are comfortable, with $1.5B liquidity.
Watch the Q2 buyback pace. The stock now trades ~$70, well below the $92 Q1 average repurchase price, so aggressive buying would be accretive — but doing so while EBITDA shrinks and leverage sits above target invites scrutiny. This is a genuine bull/bear debate: buyback-driven EPS support vs. balance-sheet discipline.
FCF cadence: management expects H2 to consume working capital (receivables build on higher daily sales), so Q2 FCF may look soft even if sales improve.

6. Stock & valuation

At ~$70, BLDR trades around ~9x EV/EBITDA on the midpoint of FY26 guidance (~$1.3B) — but that multiple is highly sensitive to which end of the $1.1B–$1.5B range proves right.
The stock has de-rated hard and underperformed the builders, so sentiment is washed out. That cuts both ways: a genuinely reassuring H2 ramp / stable specialty margins could spark a relief rally, while another guide-down likely gets punished less severely than it would have at higher levels.

7. Bottom line — scenarios into the print

Bull case: Q2 sales toward the high end (~$4.0B), EBITDA ≥$350M with margin holding ~9%, specialty margins stabilizing, cost actions visibly flowing through, and management reaffirming the FY EBITDA range with a credible back-half ramp. Aggressive sub-$75 buybacks add support.
Bear case: EBITDA at/below $300M, continued specialty-margin and price/cost erosion, softening private-builder demand amid renewed Middle East/rate volatility, and another FY cut (especially trimming the top of the $1.5B EBITDA range). Leverage creeping toward the high-3s adds pressure.

What I'd watch first on the tape: (1) reported gross margin vs. the 27.5%–29% FY frame and whether specialty stabilized; (2) whether FY EBITDA guidance is reaffirmed, raised, or cut; (3) Q2 buyback dollars and updated leverage; (4) any change to the "H2-weighted / multi-family recovers in 2027" framing. Given how far the stock has fallen, the reaction will hinge more on the forward guide and margin trajectory than on the Q2 headline itself.

Note: The figures above are anchored to BLDR's own Q1 2026 disclosures and explicit Q2/FY guidance rather than to a formal published sell-side consensus, which I couldn't independently verify in the available sources. Treat management's Q2 ranges ($3.75B–$4.05B sales; $300M–$350M adj. EBITDA) as the effective "bar."